Navigation Links
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
Date:7/21/2014

e SYN-005 antibody combination.

In April 2014, Synthetic Biologics reported positive preclinical results from non-human primate, Pertussis studies of SYN-005, which were associated with favorable decreases in white blood cell counts within two days of treatment and the achievement of nearly normal levels within one week.

"We are pleased to have Dr. Maynard share the research and strong body of evidence supporting the clinical development of SYN-005," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "Based on the positive non-human primate and murine model findings, Synthetic Biologics has begun manufacturing SYN-005, and remains on track to file an IND to support a Phase I clinical trial expected to initiate during the first half of 2015. In addition, we have submitted an Orphan Drug designation request for SYN-005 for the treatment of Pertussis."

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.synthetic
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Synthetic Biologics Reports Second Quarter 2012 Financial Results
4. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
5. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
6. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
7. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
8. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
9. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
10. Synthetic Biologics to Present at the 25th Annual ROTH Conference
11. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
(Date:8/27/2015)... BIRMINGHAM, Ala. , Aug. 27, 2015 ... Integrated Outpatient Pharmacy Provider (IOPP™) is expanding ... launch of a medication-focused transition of care ... program, named "RxCare Management," provides hospitals with ... improve hospital performance measures that have been ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... 2 clinical study of NKTR-102 in patients with metastatic ... Cancer Symposium in San Francisco, California.  NKTR-102 is a ... conjugate technology, and is being developed in multiple tumor ...
... The Board of the European Fine Chemicals ... to ratify the proposal of the US Food and Drug ... the help of EFCG and US industry representatives, to deliver ... (GDUFA). GDUFA requires the FDA to commit to ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... this software allows businesses to track product movement from beginning to end. , Businesses ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
(Date:8/28/2015)... ... August 28, 2015 , ... Researchers ... comprehensive information on two new duals programs: Rhode Island Integrated Care Initiative, ... Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. The database also ...
(Date:8/28/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... in order to ease the stress on the atmosphere, and lessen the number and ... the real cause of global warming and urges them to look into his studies ...
Breaking Medicine News(10 mins):Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... Enhanced design now features End-of-Life capability and longer ... LLC, a leading supplier of batteries for implantable ... enhanced Lithium Carbon Monofluoride (Li/CFx) battery technology with ... the market. The technology includes a proprietary new ...
... Remote Magnetic Navigation prominently featured on the HRS 2009 ... STXS ) said today that the Heart Rhythm ... in which its Niobe system is either featured or ... presentations include new efficacy data on the use of ...
... takes shared responsibility to a whole new level. ... saving $2 trillion in healthcare costs over the next ... is within our grasp.Blue Shield of California has long ... We are pleased that these groups are embracing the ...
... emerging pandemic of a new strain of influenza A (H1N1) ... , Researchers from the MRC Centre for Outbreak Analysis and ... World Health Organisation and public health agencies in Mexico, have ... Their key findings are as follows: , , ...
... Drug Information Association (DIA), the premiere neutral, global, multidisciplinary association ... the launch of its new online Career Center--a highly targeted ... ... Horsham, PA, USA (Vocus) May 11, 2009 -- The ...
... on Kidz-Med Thermofocus(R) 5-in-1WESTON, Fla., May 11 American ... revenue results for the first quarter ending March 31, ... with net sales of $263,603 for the first quarter ... for the first quarter of 2008.The sales increase was ...
Cached Medicine News:Health News:EaglePicher Medical Power Announces New Li/CFx Battery Technology 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 3Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 4Health News:Swine flu: Early findings about pandemic potential reported in new study 2Health News:Drug Information Association (DIA) Launches New Online Career Center 2Health News:Drug Information Association (DIA) Launches New Online Career Center 3Health News:American Scientific Resources, Inc. Releases First Quarter Revenues 2
... The BiPAP Pro with Bi-Flex bi-level system, ... that the BiPAP Pro takes to change ... Digital Auto-Trak Sensitivity™ which automatically triggers the ... pressures based on the patients breathing rhythm. ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
Medicine Products: